We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+19.82%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$416M
AUM Growth
+$20.5M
Cap. Flow
-$31M
Cap. Flow %
-7.46%
Top 10 Hldgs %
81.96%
Holding
49
New
14
Increased
9
Reduced
7
Closed
12

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$38.9M
2
INSM icon
Insmed
INSM
+$33.2M
3
VRNA
Verona Pharma
VRNA
+$28.6M
4
TRVI icon
Trevi Therapeutics
TRVI
+$8.16M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.96M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$49.9M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$29M
3
ACLX
Arcellx
ACLX
+$15M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$14.9M
5
NUVL
Nuvalent
NUVL
+$6.44M

Sector Composition

Rank Sector Weight
1 Healthcare 93.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
26
Ultragenyx Pharmaceutical
RARE
$2.45B
$1.52M 0.37%
+41,830
New +$1.51M
UTHR icon
27
United Therapeutics
UTHR
$25.8B
$1.44M 0.35%
5,000
– –
MREO
28
Mereo BioPharma
MREO
$54.7M
$1.29M 0.31%
475,361
+54,002
+13% +$130K
PTGX icon
29
Protagonist Therapeutics
PTGX
$8.79B
$1.27M 0.31%
22,951
-310,900
-93% -$14.9M
XENE icon
30
Xenon Pharmaceuticals
XENE
$6.06B
$1.25M 0.3%
40,000
– –
BHVN icon
31
Biohaven
BHVN
$2.03B
$1.13M 0.27%
+80,000
New +$1.43M
RNAM
32
DELISTED
Avidity Biosciences
RNAM
$983K 0.24%
+34,600
New +$1.03M
KNSA icon
33
Kiniksa Pharmaceuticals
KNSA
$5.8B
$808K 0.19%
+29,200
New +$743K
MLYS icon
34
Mineralys Therapeutics
MLYS
$2.25B
$556K 0.13%
+41,100
New +$596K
NAMS icon
35
NewAmsterdam Pharma
NAMS
$3.25B
$495K 0.12%
+27,319
New +$498K
JANX icon
36
Janux Therapeutics
JANX
$925M
$462K 0.11%
20,000
-18,100
-48% -$477K
TVTX icon
37
Travere Therapeutics
TVTX
$5.2B
$457K 0.11%
30,900
– –
ACLX
38
DELISTED
Arcellx
ACLX
– –
-229,085
Closed -$15M
CNTA
39
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-35,226
Closed -$507K
ISRG icon
40
Intuitive Surgical
ISRG
$127B
– –
-3,500
Closed -$1.73M
LLY icon
41
PUT
Eli Lilly
LLY
$1.02T
– –
-45,000
Closed -$37.2M
NBIX icon
42
Neurocrine Biosciences
NBIX
$16.8B
– –
-14,700
Closed -$1.63M
NUVL
43
DELISTED
Nuvalent
NUVL
– –
-90,745
Closed -$6.44M
RYTM icon
44
Rhythm Pharmaceuticals
RYTM
$6.81B
– –
-50,000
Closed -$2.65M
SLNO
45
CALL
DELISTED
Soleno Therapeutics
SLNO
– –
-100,000
Closed -$7.14M
SLNO
46
PUT
DELISTED
Soleno Therapeutics
SLNO
– –
-136,900
Closed -$9.78M
VRDN icon
47
Viridian Therapeutics
VRDN
$2.09B
– –
-160,000
Closed -$2.16M
ORKA
48
Oruka Therapeutics
ORKA
$5.82B
– –
-7,380
Closed -$75.7K
ITCI
49
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-219,719
Closed -$29M
1
2

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $498M AUM 20.41% 1-Year Est. Return

Artia Global Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Artia Global Partners held 49 positions worth $416M, up 5.2% from $395M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Artia Global Partners withdrew a net $31M in Q2 2025, closing 12 positions and reducing 7 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 86% a quarter earlier.

Against the trend, Artia Global Partners opened a new position in Trevi Therapeutics worth $7.18M.

  • Artia Global Partners's largest Q2 2025 buy was Trevi Therapeutics: 1,311,840 shares worth $7.18M.
  • Artia Global Partners added most to argenx in Q2 2025, an estimated $38.9M increase.
  • Artia Global Partners's biggest Q2 2025 reduction was Eli Lilly, cutting an estimated $49.9M.
  • Artia Global Partners fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $29M.
  • Artia Global Partners's ten largest holdings make up 82% of its $416M portfolio in Q2 2025.
  • Artia Global Partners opened 14 new positions and closed 12 in Q2 2025.
  • Artia Global Partners's portfolio value rose 5.2% quarter-over-quarter to $416M.

Based on Artia Global Partners's 13F filing for Q2 2025, filed 14 Aug 2025.